drugset / Trial / NCT01702844
Single Arm on the Tolerability of Weekly Nab-paclitaxel
Phase 2
Completed
42 enrolled
UNC Lineberger Comprehensive Cancer Center
Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)
Timeline
- Start
- 2013-06-25
- Primary completion
- 2017-06-23
- Completion
- 2019-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 100 mg/m2 | Intravenous |